Jasper Therapeutics, Inc. announced additional positive Phase 1b/2a data on briquilimab as a conditioning agent in the treatment of Fanconi Anemia (FA). The data was presented at the 2024 Stanford Medicine Center for Definitive and Curative Medicine Symposium on March 13, 2024, in Palo Alto, California. The ongoing investigator initiated Phase 1b/2a clinical trial is evaluating a conditioning regimen that includes intravenous briquilimab As a potential treatment for FA patients in bone marrow failure.

Data from the study show that briquilimab infusion has a promising safety profile and appears to be well tolerated in patients with FA, with all six patients treated achieving full donor engraftment and full blood count recovery. Treatment may include blood transfusions or medicine to create more red blood cells, but a hematopoietic stem cell transplant (HSCT) is currently the only cure. About Phase 1/2 clinical trial (NCT04784052) The Stanford sponsored, investigator initiated Phase 1/2 study is an open-label clinical trial evaluating briquilimab as an potential treatment for FA patients in Bone marrow failure (BMF) requiring allogeneic transplant.

Utilizing briquilimab, the regimen eliminates the need for busulfan chemotherapy or total body irradiation. The primary outcomes include safety, efficacy, and engraftment success.